AI 'Smart Family Doctor' support for people after CABG or PCI
Official title: "Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft Patients or Post Percutaneous Coronary Intervention Patients
Run by China National Center for Cardiovascular Diseases · NCT06615609 · Data updated 2026-11-12
We will test whether an AI-assisted smartphone 'Smart Family Doctor' program helps adults after coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) better control blood pressure, blood sugar, and cholesterol.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 536 (estimated) |
| Sponsor | China National Center for Cardiovascular Diseases Government |
| Locations | 1 site (Ürümqi, Xinjiang) |
| Status | Recruiting |
| Started | September 24, 2025 |
| Main results expected | September 15, 2026 |
| Study ends | November 15, 2026 |
| Registry record updated | December 8, 2025 |
| Trial ID | NCT06615609 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who have had CABG or PCI, have hypertension, diabetes, and dyslipidemia meeting the study thresholds (elevated BP, HbA1c, or LDL-C), can use a smartphone, and can give informed consent are ideal candidates.
✕Probably not a fit
Patients with heart failure, severe arrhythmias, advanced organ failure, active cancer, pregnancy, cognitive or communication impairments, or those without a smartphone are unlikely to benefit or may be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized controlled trial enrolling about 536 adults across multiple hospitals to compare an AI-assisted digital health management tool plus health manager support with usual care for secondary prevention after CABG or PCI. Eligible participants are adults (≥18) with prior CABG or PCI who also have hypertension, diabetes, and dyslipidemia and meet specified thresholds for blood pressure, HbA1c, or LDL-C. Participants will be randomized and followed to measure improvements in control rates of hypertension, diabetes, and dyslipidemia using the smartphone platform and manager-driven interventions. The primary outcomes are risk-factor control rates; data will be collected through the app, clinician visits, and routine labs.
Why it matters
Potential benefit: If successful, the program could improve blood pressure, glucose, and cholesterol control in post-CABG and post-PCI patients and lower their risk of future cardiac events.
How similar studies have gone: Previous smartphone and telehealth programs for cardiac secondary prevention have shown modest improvements in risk-factor control, but fully AI-driven 'family doctor' management approaches remain relatively new and less well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * History of CABG surgery or PCI with history of hypertension, diabetes, and dyslipidemia. * At least one of the following criteria is meet: * Systolic blood pressure no less than 130 mmHg or diastolic blood pressure no less than 80 mmHg * HbA1c no less than 7% * LDL-C no less than 1.4 mmol/L * Use of a smartphone. * Signed informed consent. Exclusion Criteria: * History of heart failure or severe arrhythmias. * Presence of other severe underlying conditions such as cancer or liver and kidney insufficiency. * Pregnancy, lactation, or plans for pregnancy within the next year. * Cognitive, communication impairments, or limitations in daily activities.
Where it's running
-
Xinjiang's First Affiliated Hospital of medical university
Ürümqi, Xinjiang, China Recruiting
Study contacts
- Principal investigator: Xin Yuan, PhD — Chinese Academy of Medical Sciences, Fuwai Hospital
- Study coordinator: Lihua Zhang Zhang, PhD
- Email: zhanglihua@fuwai.com
- Phone: 8601060866780
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating body fat distribution and its impact on metabolic diseases in Japanese adults
This study looks at how the way body fat is distributed affects the risk of metabolic and heart diseases in Japanese adults.
-
Linking social care with healthcare to help manage chronic diseases
This trial tests whether pairing patients with trained community health workers can help them get transportation, healthy food, information, and better access to care to improve health in conditions like hypertension, diabetes, and high cholesterol.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
Home-based cardiovascular health screening for people turning 50, 55, 60, 65, 70 or 75 in Uppsala
This trial tests whether giving people a home blood pressure monitor, a dried blood spot kit, and a questionnaire can find more cardiovascular risk factors than usual care.
-
Digital health platform to help prevent and manage high blood pressure, lipids, and kidney and heart disease
This trial tests a mobile digital health platform to help people with hypertension, dyslipidemia, and related conditions in New Taipei City see if the platform improves blood pressure, cholesterol, and kidney health.
-
Community-based exercise and lifestyle program for people at risk of metabolic syndrome
A community program tests whether a structured exercise and lifestyle plan can improve heart and blood health in people with hypertension, high cholesterol, or high blood sugar.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.